Point of Care Testing for Systemic Lupus Erythematosus (SLE) Market Research Report - Segmented by Technology Type (Immunofluorescence Assays, Enzyme-Linked Immunosorbent Assays, Molecular Diagnostics); By Diagnostic Test (Antinuclear Antibody Test, Autoantibody Test, Compliment Component Test); By End-User (Hospitals, Clinics, Home Care); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-15477
Format:
Region: Global
Chapter 1. Point of Care Testing for SLE Market - Scope & Methodology
1.1 Market Segmentation
1.2 Assumptions
1.3 Research Methodology
1.4 Primary Sources
1.5 Secondary Sources
Chapter 2. Point of Care Testing for SLE Market - Executive Summary
2.1 Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2 Key Trends & Insights
2.3 COVID-19 Impact Analysis
2.3.1 Impact during 2023 – 2030
2.3.2 Impact on Supply – Demand
Chapter 3. Point of Care Testing for SLE Market - Competition Scenario
3.1 Market Share Analysis
3.2 Product Benchmarking
3.3 Competitive Strategy & Development Scenario
3.4 Competitive Pricing Analysis
3.5 Supplier - Distributor Analysis
Chapter 4. Point of Care Testing for SLE Market - Entry Scenario
4.1 Case Studies – Start-up/Thriving Companies
4.2 Regulatory Scenario - By Region
4.3 Customer Analysis
4.4 Porter's Five Force Model
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Powers of Customers
4.4.3 Threat of New Entrants
4.4.4 Rivalry among Existing Players
4.4.5 Threat of Substitutes
Chapter 5. Point of Care Testing for SLE Market - Landscape
5.1 Value Chain Analysis – Key Stakeholders Impact Analysis
5.2 Market Drivers
5.3 Market Restraints/Challenges
5.4 Market Opportunities
Chapter 6. Point of Care Testing for SLE Market - By Technology Type
6.1 Immunofluorescence Assays (IFA)
6.2 Enzyme-Linked Immunosorbent Assays (ELISA)
6.3 Molecular Diagnostics (PCR-based)
Chapter 7. Point of Care Testing for SLE Market - By Diagnostic Test
7.1 Antinuclear Antibody (ANA) Test
7.2 Autoantibody Test
7.3 Compliment Component Test
7.4 Other Tests
Chapter 8. Point of Care Testing for SLE Market - By End-User
8.1 Hospitals
8.2 Clinics
8.3 Home Care
8.4 Other
Chapter 9. Point of Care Testing for SLE Market – By Region
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Latin America
9.5 The Middle East
9.6 Africa
Chapter 10. Point of Care Testing for SLE Market – Key players
10.1 Perfern RF
10.2 Rapid Labs
10.3 Arlington Scientific
10.4 Avantor
10.5 Atlas Medical
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Global Point of Care Testing for Systemic Lupus Erythematosus (SLE) Market was valued at USD 1.08 billion in 2022 and is projected to reach USD 1.97 billion by 2030, exhibiting a robust CAGR of 7.8% during the forecast period from 2023 to 2030.
The increasing prevalence of Systemic Lupus Erythematosus, the advantages of Point of Care Testing, and growing awareness of early disease detection are the market drivers for Point of Care Testing for SLE.
The segments under the Point of Care Testing for the SLE market by Test Type include Antinuclear Antibody (ANA) Test, Anti-dsDNA Test, Anti-Smith (Sm) Test, and Other Tests.
The Asia-Pacific region is the fastest growing due to increasing healthcare expenditure, rising awareness of SLE, and the adoption of advanced diagnostic technologies in the region.
North America currently holds the largest share in the Point of Care Testing for Systemic Lupus Erythematosus (SLE) market, driven by the region's well-established healthcare infrastructure and high awareness about SLE and POCT solutions.
